GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: GW685698X aqueous nasal spray

First Posted Date: 2005-07-01

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 90

Registration Number: NCT00116883

Locations: 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Phase 3

Completed

Conditions: Atherosclerosis

Interventions: Drug: rosiglitazone maleate
Drug: Glipizide

First Posted Date: 2005-07-01

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 672

Registration Number: NCT00116831

Locations: 🇹🇭
GSK Investigational Site, Chiang Mai, Thailand

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Phase 4

Completed

Conditions: Infections, Herpesviridae

Interventions: Drug: Valaciclovir
Drug: Placebo

First Posted Date: 2005-07-01

Last Posted Date: 2018-02-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT00116844

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Hayfever
Rhinitis, Allergic, Seasonal
Seasonal Allergic Rhinitis

First Posted Date: 2005-06-24

Last Posted Date: 2016-09-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 304

Registration Number: NCT00115622

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-06-23

Last Posted Date: 2017-01-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 797

Registration Number: NCT00115492

Locations: 🇨🇦
GSK Investigational Site, Trois Rivieres, Quebec, Canada

Dental Pain (Following Third Molar Tooth Extraction) Study

Phase 3

Completed

Conditions: Surgery, Dental
Dental Pain

First Posted Date: 2005-06-14

Last Posted Date: 2017-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT00114049

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2005-06-08

Last Posted Date: 2017-03-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2208

Registration Number: NCT00113308

Locations: 🇬🇧
GSK Investigational Site, Northampton, Northamptonshire, United Kingdom

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Phase 3

Completed

Conditions: Epilepsy, Partial
Epilepsy

First Posted Date: 2005-06-07

Last Posted Date: 2016-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 244

Registration Number: NCT00113165

Locations: 🇺🇦
GSK Investigational Site, Lviv, Ukraine

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib
Drug: Paclitaxel

First Posted Date: 2005-05-26

Last Posted Date: 2017-05-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 49

Registration Number: NCT00111787

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A New Oral Treatment For Type II Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: DEN 15 mg
Drug: Placebo
Drug: DEN 30 mg
Drug: DEN 2.5 mg
Drug: DEN 7.5 mg
Drug: DEN 45 mg

First Posted Date: 2005-05-26

Last Posted Date: 2018-03-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 375

Registration Number: NCT00111800

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy